Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition
All content on this site: Copyright © 2025 AME Publishing Company. All rights are reserved. For all open access content, the Creative Commons licensing terms apply.
Published by AME Publishing Company
Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.
Email: editor@thehbsn.org
Comments (0)